1.27
+0.05(+4.10%)
Currency In USD
| Previous Close | 1.22 |
| Open | 1.18 |
| Day High | 1.3 |
| Day Low | 1.16 |
| 52-Week High | 4.49 |
| 52-Week Low | 0.53 |
| Volume | 188,117 |
| Average Volume | 150,508 |
| Market Cap | 16.93M |
| PE | -1.53 |
| EPS | -0.83 |
| Moving Average 50 Days | 1.99 |
| Moving Average 200 Days | 2.16 |
| Change | 0.05 |
If you invested $1000 in Nexalin Technology, Inc. (NXL) since IPO date, it would be worth $564.44 as of May 09, 2025 at a share price of $1.27. Whereas If you bought $1000 worth of Nexalin Technology, Inc. (NXL) shares 2 years ago, it would be worth $1,477.6 as of May 09, 2025 at a share price of $1.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
GlobeNewswire Inc.
May 06, 2025 6:40 PM GMT
HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announc
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
GlobeNewswire Inc.
May 05, 2025 12:20 PM GMT
HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the pricing of an underwritten public
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
GlobeNewswire Inc.
May 01, 2025 2:30 PM GMT
Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indicationsHOUSTON, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), today announced